

HEALTHCARE EQUITY: IS IT FAIR?




*“Equity is the absence of **unfair, avoidable or remediable differences** among groups of people, whether those groups are defined **socially, economically, demographically, or geographically** or by **other dimensions** of inequality (e.g. sex, gender, ethnicity, disability, or sexual orientation).”*



THE JOURNEY TOWARDS HEALTHCARE EQUITY FOR RARE DISEASES

Cogentia[®]



Children in sub-Saharan Africa

14x

more likely to die

87%

of premature deaths in low- and
middle-income countries

Developing countries account for

99%

of annual maternal deaths in the world


Life expectancy varies by

34 years



REGIONAL DISPARITIES IN EUROPE

**Innovative Treatments - Time to availability
(2017-2020)**



Complex regulatory environments



Budget constraints



Policy influence



Manufacturing and supply chain issues

Source: W.A.I.T Indicator Survey 2021 Available From: https://www.efpia.eu/media/676539/efpia-patient-wait-indicator_update-july-2022_final.pdf

Disparities in health coverage

89% vs. 93%

African Americans vs. white Americans
Access to healthcare

12%

% of African Americans under the age of 65
with no healthcare coverage at all

Health implications

7% vs. 4%

African Americans vs. white Americans
Stroke occurring in the 50-64 aged years

32% vs. 22%

African Americans vs. white Americans
High blood pressure in the 35-49 aged years



POTENTIAL BARRIERS

Regulatory hurdles

The intricacy of approval processes



Discrepancies in regulatory requirements across countries



The limited availability of clinical trials for underserved



Economic & logistical challenges

Securing adequate funding remains a challenge



The complexity of medicine distribution



The high cost of certain therapies



Cultural and social obstacles

Lack of cultural competence in healthcare



Stigma associated with certain diseases



Language barriers and health literacy





Situation to
address

x2

Twice as likely to develop MM
compared to White Americans

20%

20% of MM cases, despite
comprising 13.4% of the US pop.

37%

37% less likely to have a stem cell
transplant vs White Americans.

Key objectives
and actions

Increase awareness about the unique impact of MM on African Americans

Support patient education on standards of care and support services



Provide healthcare professionals with educational programs



- ✓ **20+ different educational materials produced (e.g. clinical trial brochure to address disparities and myths, distributed to over 60 clinical trial sites in the U.S)**
- ✓ **Supported over 40 speaker programs with nearly 2,000 healthcare professional attendees**
- ✓ **First Facebook page dedicated to African Americans affected by MM with over 61,000 followers**
- ✓ **Increased awareness and detection rates of MM among African Americans**



'TOWARDS A FUTURE OF HEALTHCARE EQUITY' – WHAT CAN PHARMA COMPANIES DO TO MITIGATE DISPARITIES IN RARE DISEASES?

1	Process Awareness	Develop an awareness of current and upcoming processes which could potentially benefit healthcare equity	 European Joint Clinical Assessment (JCA)
2	Market Access Strategy	Ensure integration of equity into your market access strategy	 Equity Roles within Market Access Teams
3	Tailored Solutions	Recognise that rare diseases require nuanced and tailored solutions	NICE National Institute for Health and Care Excellence Distributional Cost-Effectiveness Analysis in Haematology



Cogentia[®]



ABBEY
Child

Senior Consultant

Our Advanced
Therapeutics White Papers:



Gene Therapies



Stem Cell Therapies

Come and meet us at EPA Stand No. 146

[+44 \(0\) 1223 967276](tel:+441223967276)

abbey.child@cogentia.co.uk

cogentia.co.uk